Compare Cognizant Technology Solutions Corp (CTSH) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Medpace Holdings Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Medpace Holdings Inc for 14 Days on average.
| CTSH | MEDP | |
|---|---|---|
Market Cap | $27.03B | $16.82B |
Volume | 9,883,888 | 223,093 |
Sector | Technology | Health |
52-Week High | $86.70 | $630.19 |
52-Week Low | $38.73 | $393.42 |
Typical Hold Time | 57 Days | 14 Days |
Enterprise Value | $28.08B | $16.44B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $60.01, up 5.15% with a bullish technical signal. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed. The company shows solid fundamentals with a P/E of 12.88 and net income margin of 10.26%. Positive news includes AI partnerships and employer awards, supporting investor confidence.
The outlook is positive with a consensus price target of $64.25, indicating potential upside. Risks include competitive pressures in IT services and reliance on AI adoption. Strong cash flow and low debt bolster stability, but market volatility and economic headwinds remain concerns for sustained growth.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
